Skip to main content
. 2024 Oct 7;66(1):e15798. doi: 10.1111/ped.15798

TABLE 3.

QBB2‐1, number of subjects with treatment‐related adverse events (TRAEs) and number of TRAEs.

TRAEs IGA 2 (mild) IGA 3,4 (moderate and severe) Total
Vehicle Delgocitinib 0.25% ointment Delgocitinib 0.5% ointment Vehicle Delgocitinib 0.25% ointment Delgocitinib 0.5% ointment Vehicle Delgocitinib 0.25% ointment Delgocitinib 0.5% ointment
n 13 13 14 22 21 20 35 34 34
N (%) e N e N e N e N e N e N e N e N e N
Total 1 1 (7.7) 1 1 (7.7) 0 0 (0.0) 1 1 (4.5) 0 0 (0.0) 1 1 (5.0) 2 2 (5.7) 1 1 (2.9) 1 1 (2.9)
Infections and infestations 1 1 (7.7) 1 1 (7.7) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (5.0) 1 1 (2.9) 1 1 (2.9) 1 1 (2.9)
Impetigo 1 1 (7.7) 1 1 (7.7) 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (5.0) 1 1 (2.9) 1 1 (2.9) 1 1 (2.9)
Skin and subcutaneous tissue disorders 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (4.5) 0 0 (0.0) 0 0 (0.0) 1 1 (2.9) 0 0 (0.0) 0 0 (0.0)
Dermatitis contact 0 0 (0.0) 0 0 (0.0) 0 0 (0.0) 1 1 (4.5) 0 0 (0.0) 0 0 (0.0) 1 1 (2.9) 0 0 (0.0) 0 0 (0.0)

Note: TRAEs coded according to MedDRA/J 19.1.

Abbreviations: IGA, investigator’s global assessment; e, number of events; N, number of patients.